Clinical trial • Phase I/II • Oncology
Clinical trial in Metastatic esophagogastric cancer
Phase I/II trial for Metastatic esophagogastric cancer. 61 participants.
Overview
- Trial Therapeutic Area
- Oncology
- Trial Disease
- Metastatic esophagogastric cancer
- Trial Stage
- Phase I/II
- Drug Modality
- Small molecule
Key dates
- Initial CTIS Submission Date
- 12-03-2025
- First CTIS Authorization Date
- 01-07-2025
Trial design
Phase I/II trial across 1 site in Netherlands.
- Target Sample Size
- 61
Eligibility
Recruits 61 Vulnerable population not selected; no specific consent/assent handling described..
- Vulnerable Population
- Vulnerable population not selected; no specific consent/assent handling described.
Recruitment
- Planned Sample Size
- 61
- Recruitment Window Months
- 48
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 61
Netherlands
- Earliest CTIS Part Ii Submission Date
- 23-06-2025
- Latest Decision Or Authorization Date
- 09-04-2026
- Processing Time Days
- 290
- Number Of Sites
- 1
- Number Of Participants
- 61
Sites
- Site Name
- Amsterdam UMC Stichting
- Department Name
- Medische Oncologie
- Contact Person Name
- Hanneke van Laarhoven
- Contact Person Email
- medonc-uppergi@amsterdamumc.nl
- Number Of Participants
- 61
Sponsor
Primary sponsor
- Full Name
- Amsterdam UMC Stichting
- Organisation Type
- Patient organisation/association
- Country Of Registered Address
- Netherlands
Investigational products
- Combination Treatment
- Yes
Related trials
Other published trials that may interest you.
- GDC-9545 for Locally advanced or metastatic estrogen receptor-positive breast cancer
- Abemaciclib for Stage IV lung cancer | Breast cancer
- BGB-43395 for Advanced or metastatic solid tumors | Hormone receptor positive HER2 negative breast cancer
- AZD9833 for Estrogen receptor-positive HER2-negative advanced breast cancer
- Pembrolizumab for Classical Hodgkin lymphoma | Melanoma | Solid tumours (MSI-H/dMMR) | Solid tumours (TMB-H)